Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 12, Pages 4880-4898Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm400048v
Keywords
-
Categories
Funding
- NIH
- NCI [R21 CA11791-01, 1RO1CA129379-01 A2, 5RO1CA129379-02]
- Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA, U.S.
- University of Maryland School of Medicine
- Center for Biomolecular Therapeutics (CBT), Baltimore, MD, U.S.
- University of Maryland School of Medicine Toxicology Program
Ask authors/readers for more resources
As part of our program to explore the influence of small structural modifications of our drug candidate 3 beta-(hydroxy)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (galeterone, 5) on the modulation of the androgen receptor (AR), we have prepared and evaluated a series of novel C-3, C-16, and C-17 analogues. Using structure activity analysis, we established that the benzimidazole moiety at C-17 is essential and optimal and also that hydrophilic and heteroaromatic groups at C-3 enhance both antiproliferative (AP) and AR degrading (ARD) activities. The most potent antiproliferative compounds were 3 beta-(1H-imidazole-1-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (47), 3-((EZ)-hydroximino)-17-(1H-benzimidazol-1-yl)androsta-4,16-diene (36), and 3 beta-(pyridine-4-carboxylate)-17-(1H-benzimidazol-1-yl)androsta-5,16-diene (43), with GI(50) values of 0.87, 1.91, and 2.57 mu M, respectively. Compared to 5, compound 47 was 4- and 8-fold more potent with respect to AP and ARD activities, respectively. Importantly, we also discovered that our compounds, including 5, 36, 43, and 47, could degrade both full-length and truncated ARs in CWR22rv1 human prostate cancer cells. With these activities, they have potential for development as new drugs for the treatment of all forms of prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available